Sanuwave Health’s (SNWV) Buy Rating Reiterated at Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of Sanuwave Health (NASDAQ:SNWV) in a report issued on Monday,Benzinga reports. Roth Mkm currently has a $47.00 price target on the stock, down from their prior price target of $53.00.

A number of other analysts have also recently commented on SNWV. Wall Street Zen cut Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings raised Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.00.

Sanuwave Health Trading Down 2.5%

Shares of NASDAQ SNWV opened at $16.85 on Monday. Sanuwave Health has a 1 year low of $16.27 and a 1 year high of $46.58. The company has a debt-to-equity ratio of 10.08, a current ratio of 1.38 and a quick ratio of 1.05. The firm has a 50-day moving average of $23.41 and a 200 day moving average of $28.98. The stock has a market cap of $144.74 million, a P/E ratio of -105.31 and a beta of 1.52.

Sanuwave Health (NASDAQ:SNWV) last announced its quarterly earnings data on Thursday, March 26th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14). Sanuwave Health had a negative return on equity of 141.56% and a net margin of 26.64%.The business had revenue of $13.09 million during the quarter, compared to analysts’ expectations of $13.23 million.

Institutional Trading of Sanuwave Health

A number of institutional investors and hedge funds have recently bought and sold shares of SNWV. Praetorian PR LLC lifted its stake in shares of Sanuwave Health by 1,436.2% in the fourth quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock worth $7,908,000 after buying an additional 247,750 shares in the last quarter. Stifel Financial Corp bought a new stake in shares of Sanuwave Health during the fourth quarter valued at approximately $5,291,000. Geode Capital Management LLC bought a new stake in shares of Sanuwave Health during the second quarter valued at approximately $5,184,000. CenterBook Partners LP raised its holdings in Sanuwave Health by 528.7% in the 3rd quarter. CenterBook Partners LP now owns 87,947 shares of the company’s stock worth $3,296,000 after acquiring an additional 73,959 shares during the last quarter. Finally, Stonebridge Wealth Management LLC purchased a new position in Sanuwave Health in the 2nd quarter worth approximately $1,696,000. 42.53% of the stock is currently owned by institutional investors.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.